Breakthrough Isolaz Pro to Launch into High Growth Brazilian Market for Aesthetic and Medical Procedures
PLEASANTON, Calif., May 20 /PRNewswire/ -- Aesthera announced today the receipt of ANVISA clearance to market their proprietary Isolaz Pro photopneumatic(TM) based platforms in Brazil. ANVISA (Agencia Nacional de Vigilancia Sanitaria) is a Brazilian national health surveillance and regulatory agency charged with clearing all applications to market medical devices in Brazil.
Aesthera also announced its partner in the region, Sao Paulo based LBT Lasers, a leading distributor of advanced aesthetic technology solutions for physician practices. Aesthera's Isolaz Pro and other soon to be launched technologies will be exclusively represented by LBT sales professionals in the Brazilian market.
"This is the most recent milestone in our aggressive build-out of Aesthera's international distribution channel. We look forward to partnering with LBT Lasers as we introduce the Isolaz Pro(TM) to Brazilian physicians," said Alon Maor, president and CEO of Aesthera Corp. Aesthera's Isolaz platform is the only FDA cleared device for the treatment of comedonal and pustular acne, in addition to being cleared for the skin rejuvenation and hair removal. "LBT Lasers has a longstanding reputation as a premier provider of innovative aesthetic technology. Their strong network coupled with large customer base of over 300 physician offices will accelerate the rapid adoption of Photopneumatic platforms to over 5000 dermatologists in the Brazilian marketplace," he adds.
"The Isolaz Pro platform will offer Brazilian physicians a much needed treatment solution for acne as well as Profusion - a breakthrough skin therapy to enhance skin treatment outcomes for acne, body tightening, skin rejuvenation and skin lightening," says Alexandre Ferraz, CEO, LBT Laser. "We are proud that Aesthera has selected LBT Lasers as their exclusive distributor in our region. The addition of Aesthera's products to our offering demonstrates our commitment to bringing only the most innovative and effective technologies to our Brazilian customers. The Brazilian market for aesthetics is strongly positioned for continued robust growth in the coming years," he adds.
Aesthera's Isolaz platform will be launched to the Brazilian market at key academic meetings starting with the Teraderm - Sociedade Brasileira de Dermatologia meeting (May 22 - 23, 2009), the Congresso Brasileiro de Medicina Estetica (June 3 - 6, 2009) and the upcoming Congresso Brasileiro de Cirurgia Dermatologica between June 10 - 14, 2009.
About Photopneumatic(TM) Technology
Photopneumatic Therapy, that powers the Isolaz(TM) and Isolaz Pro(TM) system, is a proprietary combination of pneumatic energy and broad band light. Photopneumatic devices are the only laser or light based devices cleared for the treatment of inflammatory acne, comedonal acne and pustular acne. They are also cleared for the treatment of mild to moderate inflammatory acne. Photopneumatic treatments have an immediate visible impact on acne 24 - 48 hour post first treatment and are painless. Facial treatments take approximately 10 minutes, require no anesthetics or numbing creams and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal.
About Aesthera Corporation
Aesthera (www.AESTHERA.com) develops, manufactures and markets light-based aesthetic treatment systems - the Isolaz(TM) and Isolaz Pro(TM) platforms - based on proprietary Photopneumatic(TM) technology.
Contact: Sarvar Kothavala Aesthera Corp. 415.760.0902 SKothavala@Aesthera.com
|SOURCE Aesthera Corporation|
Copyright©2009 PR Newswire.
All rights reserved